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NUTRACEUTICALS IN THE PREVENTION AND TREATMENT OF 
ATHEROSCLEROSIS 
 
H. Gallagher, J.W.E. Moss, J. Williams, T.S. Davies, W. Al-Ahmadi, V. O'Morain, D.P. 
Ramji 
Cardiff University, Cardiff, UK  
Objectives: To investigate the effects of nutraceuticals on key processes associated with 
atherosclerosis in vitro and in vivo. 
 
Background: Atherosclerosis is an inflammatory disease of the vasculature in which 
macrophages play key roles at all stages and represent promising therapeutic targets. 
Unfortunately, current therapies against atherosclerosis are not fully effective and associated 
with other issues such as adverse side effects. In addition, there have been many failures on 
pharmaceutical agents identified from drug discovery programs. Nutraceuticals represent 
promising alternatives in the prevention and treatment of atherosclerosis but requires a 
thorough understanding of their actions together with the underlying mechanisms. The 
purpose of this study was to address this with emphasis on key macrophage processes 
associated with atherosclerosis.  
Methods: A combination of macrophage cell lines and primary cultures were used with gene 
expression analysed by atherosclerosis profiler arrays and real time quantitative PCR. Foam 
cell formation was investigated by following the uptake of fluorescently labeled modified 
LDL, intracellular lipid profiling and cholesterol efflux assays. Inflammasome activation was 
evaluated by following the release of interleukin (IL)-1beta using an ELISA and ROS 
production using a kit from Abcam. The effects in vivo were analysed in C57BL/6 mice fed a 
high fat diet.  
Results: The studies focused on polyphenols, flavanols and omega-6 polyunsaturated fatty 
acids. These either inhibited or had no effect on several key macrophage processes associated 
with atherosclerosis such as pro-inflammatory gene expression, the uptake of modified LDL, 
macropinocytosis, ROS production and the activation of the inflammasome. In addition, 
where analysed, the nutraceutical inhibited several atherosclerosis-associated markers in mice 
fed a high fat diet. The mechanisms underlying such actions will be presented.  
Conclusions: The studies provide new insights into the beneficial actions of nutraceuticals in 
atherosclerosis.  
 
